All In Biotech

Drug Trial Radar · NCT04976322

A Study to Evaluate the Safety and Tolerability of Dapirolizumab Pegol in Study Participants With Systemic Lupus Erythematosus

A Multicenter, Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of Dapirolizumab Pegol Treatment in Study Participants With Systemic Lupus Erythematosus

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Enrolling by invitationPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Enrolling by invitation

Enrollment

760

Planned (sponsor's estimate)

Start

Jul 27, 2021

Primary completion

Aug 7, 2030

Study completion Aug 7, 2030

Sponsor

Lead sponsor
UCB Biopharma SRLUCB
Sponsor type
Industry
First posted
Jul 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate long-term safety and tolerability of dapirolizumab pegol treatment.

Conditions

  • Systemic Lupus Erythematosus

Interventions

  • Dapirolizumab pegolDrug

    Subjects will receive dapirolizumab pegol at prespecified time-points.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of treatment-emergent adverse events (TEAEs) during the studyTime frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
  2. Incidence of serious treatment-emergent adverse events during the studyTime frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)
  3. Incidence of treatment-emergent adverse events (TEAEs) leading to permanent dapirolizumab pegol discontinuationTime frame: From Baseline (Day 1) until Safety Follow-Up (up to Week 110)

Locations

123 sites in 24 countries. Site status is shown where the registry gives one.

  • Sl0046 50140

    Birmingham, Alabama

  • Sl0046 50058

    Avondale, Arizona

  • Sl0046 50662

    Glendale, Arizona

  • Sl0046 50052

    Phoenix, Arizona

  • Sl0046 50328

    Tucson, Arizona

  • Sl0046 50383

    Beverly Hills, California

  • Sl0046 50275

    La Palma, California

  • Sl0046 50316

    San Leandro, California

  • Sl0046 50339

    Denver, Colorado

  • Sl0046 50239

    Brandon, Florida

  • Sl0046 50362

    Gainesville, Florida

  • Sl0046 50681

    Miami, Florida

  • Sl0046 50059

    Ormond Beach, Florida

  • Sl0046 50324

    Plantation, Florida

  • Sl0046 50329

    Tampa, Florida

  • Sl0046 50698

    Tampa, Florida

  • Sl0046 50368

    Atlanta, Georgia

  • Sl0046 50240

    Idaho Falls, Idaho

  • Sl0046 50699

    Chicago, Illinois

  • Sl0046 50474

    Hopkinsville, Kentucky

  • Sl0046 50285

    Lake Charles, Louisiana

  • Sl0046 50660

    New Orleans, Louisiana

  • Sl0046 50015

    Hagerstown, Maryland

  • Sl0046 50219

    Detroit, Michigan

  • Sl0046 50273

    Las Vegas, Nevada

  • Sl0046 50366

    Canton, New York

  • Sl0046 50264

    Manhasset, New York

  • Sl0046 50334

    New York, New York

  • Sl0046 50238

    Charlotte, North Carolina

  • Sl0046 50147

    Hershey, Pennsylvania

  • Sl0046 50001

    Jackson, Tennessee

  • Sl0046 50738

    Bellaire, Texas

  • Sl0046 50418

    Colleyville, Texas

  • Sl0046 50050

    Beckley, West Virginia

  • Sl0046 60002

    Buenos Aires, Argentina

  • Sl0046 60029

    Mendoza, Argentina

  • Sl0046 60003

    Quilmes, Argentina

  • Sl0046 60022

    Quilmes, Argentina

  • Sl0046 60011

    San Juan, Argentina

  • Sl0046 60014

    San Miguel de Tucumán, Argentina

Showing 40 of 123 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.